Tag: Medtronic

Medtronic Receives Reimbursement Approval for Symplicity Spyral™ Renal Denervation System in Japan

Milestone expands patient access to the first and most studied renal denervation therapy for hypertension. DUBLIN – February 19, 2026 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted reimbursement approval for the Symplicity Spyral™ renal […]

Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolio GALWAY, Ireland, Feb. 17, 2026 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its…

Medtronic advances its innovation strategy with intent to acquire CathWorks

Deal demonstrates Medtronic’s commitment to expanding pipeline through strategic investments and targeted acquisitions Exercising option to acquire will bolster Medtronic’s interventional cardiology portfolio, expanding its leadership in transforming how cardiovascular disease is diagnosed and treated Medtronic’s intent to acquire follows a 2022 strategic partnership agreement with CathWorks GALWAY, Ireland, Feb. 3, 2026 /PRNewswire/ — Medtronic plc (NYSE:MDT), […]

Affera™ momentum continues as Medtronic announces CE Mark in Europe and U.S. IDE first cases for Sphere-360™ PFA catheter to treat paroxysmal atrial fibrillation

First-of-its-kind, rotation-free single-shot PFA catheter supported by strong safety and efficacy data adds to the groundbreaking Affera family of technologies in Europe Successful completion of first cases at multiple sites kicks off Horizon 360 IDE pivotal trial in the United States…

Medtronic Aurora EV-ICD™ system demonstrates exceptional results at six months in the Enlighten real-world post-market study while the OmniaSecure™ defibrillation lead sustains performance at three years in the LEADR Pivotal Trial

APHRS.25: Medtronic showcases breadth of defibrillation portfolio with outcomes from extravascular and transvenous defibrillation studies for the treatment of dangerous heart rhythm episodes Cardiac Rhythm Management Researchers presented results from two late-breaking presentations at the Asia Pacific Heart Rhythm Society (APHRS) Scientific Session 2025 held in Yokohama, Japan. The six-month […]

Medtronic announces launch of Stedi™ Extra Support Guidewire to enhance Medtronic TAVR system performance

Stedi Extra Support Guidewire Delivers Enhanced Support for Stability, Safety, and Predictability During Valve Deployment for Aortic Stenosis   Medtronic plc, a global leader in healthcare technology, today announced the launch of the Stedi™ Extra Support guidewire, designed to enhance performance of the Evolut™ transcatheter aortic valve replacement (TAVR) platform […]

Six-month SPYRAL AFFIRM results from Medtronic demonstrate blood pressure reductions in high-risk cardiovascular patients

Medtronic also announced completion of enrollment in SPYRAL AFFIRM, which aims to build robust real-world evidence across traditionally underserved patient populations Medtronic plc, a global leader in healthcare technology, today announced the completion of enrollment and the first results from the High Cardiovascular Risk Patient Cohort of the SPYRAL AFFIRM […]

Medtronic receives CE Mark for Penditure™ Left Atrial Appendage (LAA) Exclusion System, ushering in a new era of left atrial appendage management in Europe as it surpasses 10,000 Penditure Devices Sold Globally

Medtronic plc, a global leader in healthcare technology, today announced its Penditure™ Left Atrial Appendage (LAA) Exclusion System has officially received CE Mark approval and will be launched in Europe at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting from October 8-11 in Copenhagen, Denmark. The Penditure device recently […]